Medpace Holdings, Inc. 4

President & CEO August J. Troendle sold 42,783 shares of Medpace Holdings, Inc. common stock in open-market transactions totaling about $26 million.

On August 19 and 20, 2026, Medpace Holdings, Inc. President & CEO August J. Troendle executed open‑market sales of Medpace common stock under a limit order during an open trading window, selling 15,609 shares at a weighted average price of $606.47 and 27,174 shares at a weighted average price of $618.79. These transactions totaled 42,783 shares sold for approximately $26.0 million in gross proceeds. Following these sales, Troendle directly owned 561,195 shares of Medpace common stock, and he also has indirect beneficial ownership of an additional 4,733,019 shares held through Medpace Investors, LLC, over which he exercises sole voting and investment control but disclaims beneficial ownership except to the extent of his pecuniary interest.

Filing Facts

CIK

1668397

Ticker

MEDP

Form

4

Source Type

fda

Accession

0000892251-26-000125

Alert Tier

7